Skip to main content

PRECISION BIOSCIENCES INC

For the period ended Sep 30, 2024. Filed Nov 4, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 4, 2024

DTIL$9.68-8.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Statements of Changes in Stockholders’ Equity

Stockholders’ Equity

(In thousands, except share amounts)

Common Stock · AdditionalPaid-In · Accumulated · Treasury · TotalStockholders’
SharesAmountCapitalDeficitStockEquity
Balance- December 31, 20223,725,689$1$489,696$(428,312)$(952)$60,433
Stock option exercises1,718—30——30
Issuance of common stock under employee stock purchase plan9,303—266——266
Share-based compensation expense——4,092——4,092
Restricted stock units vested16,717—————
Proceeds from issuance of common stock, net of issuance cost18,012—416——416
Net loss———(25,060)—(25,060)
Balance- March 31, 20233,771,439$1$494,500$(453,372)$(952)$40,177
Share-based compensation expense——3,874——3,874
Proceeds from issuance of common stock, net of issuance cost77,509—1,881——1,881
Restricted stock units vested13,499—————
Net loss———(11,891)—(11,891)
Balance- June 30, 20233,862,447$1$500,255$(465,263)$(952)$34,041
Share-based compensation expense——3,105——3,105
Issuance of common stock under employee stock purchase plan8,798—104——104
Proceeds from issuance of common stock, net of issuance cost11,494—(108)——(108)
Net loss———(8,079)—(8,079)
Balance- September 30, 20233,882,739$1$503,356$(473,342)$(952)$29,063
Balance- December 31, 20234,191,053$1$509,443$(489,631)$(952)$18,861
Issuance of common stock under employee stock purchase plan9,037—112——112
Share-based compensation expense——2,906——2,906
Proceeds from issuance of common stock to collaboration partners and licensees97,360—905——905
Proceeds from issuance of common stock and warrants through underwritten offering, net of issuance cost2,500,000—4,610——4,610
Proceeds from issuance of common stock through ATM facility, net of issuance cost98,943—1,224——1,224
Restricted stock units vested46,861—————
Net income———8,588—8,588
Balance- March 31, 20246,943,254$1$519,200$(481,043)$(952)$37,206
Share-based compensation expense——2,928——2,928
Proceeds from issuance of common stock, net of issuance cost25,000—300——300
Proceeds from issuance of common stock through ATM facility, net of issuance cost144,735—1,531——1,531
Restricted stock units vested37,396—————
Net income———32,749—32,749
Balance- June 30, 20247,150,385$1$523,959$(448,294)$(952)$74,714
Share-based compensation expense——3,199——3,199
Issuance of common stock under employee stock purchase plan14,794—137——137
Proceeds from issuance of common stock through ATM facility, net of issuance cost342,357—3,241——3,241
Net loss———(16,425)—(16,425)
Balance- September 30, 20247,507,536$1$530,536$(464,719)$(952)$64,866
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.